A    B    C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z

Paper Abstract

Phase I-II study evaluating HSV-tK + valacyclovir gene therapy combined with radiotherapy and chemotherapy for newly diagnosed Anaplastic Astrocytoma and Glioblastoma Multiforme.


“Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy and chemotherapy in newly diagnosed glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA).”


This is a prospective, phase I-II study to assess the efficacy and toxicity of HSV-tk + valacyclovir gene therapy in combination with radiotherapy and standard of care chemotherapy for anaplastic astrocytoma (AA) or glioblastoma multiforme (GBM). This study is comprised of newly diagnosed patients with AA or GBM.

Clinical response will be evaluated by neurological evaluation, neuropsychological testing, and imaging studies as well as by histological examination. Blood samples will be taken for a systemic immunological response, blood counts, and liver function tests. Genetic testing of tumor tissue will be performed, including genetic analysis and cell cultures. Toxicity will be graded by the Common Terminology Criteria for Adverse Events (CTCAE) v4.03 and Radiation Therapy Oncology Group (RTOG) neuro-toxicity scores (see Appendices). Patients will also be followed to assess median time to progression and median survival.


Related clinical trials

Phase II, single arm study Of NOVOTTF-200A in bevacizumab-naive...

This is a Phase 2 study in subjects with WHO Grade III Anaplastic Astrocytoma (G3 astrocytoma) who had progressive disease during...

Phase I/II trial of repeated super-selective intraarterial cerebral infusion of...

The high-grade malignant brain tumors, glioblastoma multiforme (GBM), and anaplastic astrocytoma (AA)...


Get new content delivered directly to your inbox.